Common Contracts
2 similar Warrant Agreement contracts by Genocea Biosciences, Inc.
Genocea Biosciences, Inc. 53,365,000 Shares of Common Stock ($0.001 par value per share) and 53,365,000 Class A Warrants to Purchase up to 26,682,500 Shares of Common Stock Underwriting AgreementWarrant Agreement • January 19th, 2018 • Genocea Biosciences, Inc. • Biological products, (no disgnostic substances) • New York
Genocea Biosciences, Inc., a corporation organized under the laws of the State of Delaware (the “Company”), proposes to sell to the several underwriters named in Schedule I hereto (the “Underwriters”), for whom you are acting as representative (the “Representative”), (i) 53,365,000 shares (the “Firm Shares”) of common stock, $0.001 par value (the “Common Stock”), of the Company and (ii) 53,365,000 Class A Warrants of the Company to purchase an aggregate of 26,682,500 shares of the Common Stock (the “Firm Warrants”) of the Company. The Company also proposes to grant to the Underwriters an option to purchase up to (i) 8,004,750 additional shares of the Common Stock (the “Option Shares” and together with the Firm Shares, the “Shares”) and/or (ii) 8,004,750 additional Class A Warrants to purchase up to an additional 4,002,375 shares of the Common Stock (the “Option Warrants” and together with the Firm Warrants, the “Warrants”) (such Shares and Warrants (including the Option Shares and the
Genocea Biosciences, Inc. 1,635 Shares of Series A Convertible Preferred Stock ($0.001 par value per share) and 1,635,000 Class A Warrants to Purchase up to 817,500 Shares of Common Stock Underwriting AgreementWarrant Agreement • January 19th, 2018 • Genocea Biosciences, Inc. • Biological products, (no disgnostic substances) • New York
Genocea Biosciences, Inc., a corporation organized under the laws of the State of Delaware (the “Company”), proposes to sell to the several underwriters named in Schedule I hereto (the “Underwriters”), for whom you are acting as representative (the “Representative”), (i) 1,635 shares (the “Shares”) of the Company’s Series A preferred stock, $0.001 par value (the “Preferred Stock”), which are convertible into 1,635,000 shares of common stock, $0.001 par value (the “Common Stock”), of the Company, and (ii) 1,635,000 Class A Warrants of the Company to purchase 817,500 shares of Common Stock (the “Warrants”, such Shares and Warrants to be issued and sold by the Company being hereinafter collectively called the “Securities”). Each Share is being sold together with 1,000 Warrants, each of which Warrant to purchase 0.5 shares of Common Stock at an exercise price of $1.20 per whole share. As used herein, “Conversion Shares” means Common Stock issuable upon conversion of the Shares, and “Warran
